Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088101 · ClinicalTrials.gov registry record · Phase 1
STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors
A Phase 1 study, sponsored by Synta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00088101: Completed Phase 1 study, sponsored by Synta Pharmaceuticals.
NCT00088101 is a Phase 1 study that has completed, run by Synta Pharmaceuticals. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088101, a Phase 1 study, has completed, sponsored by Synta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, toxicity and patient tolerance of STA-5312 administered intravenously to patients with relapsed or refractory hematological malignancies and patients with solid tumors.
Interventions
- DRUG STA-5312
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2004-02 |
| Est. Completion | 2004-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088101
The ClinicalTrials.gov registry entry for NCT00088101 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synta Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STA-5312 is the first listed.
NCT00088101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088101 about?
NCT00088101 is a clinical study titled "STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors". The purpose of this study is to determine the safety, toxicity and patient tolerance of STA-5312 administered intravenously to patients with relapsed or refractory hematological malignancies and patients with solid tumors.
What is the current status of trial NCT00088101?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2004-02. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00088101?
The interventions under investigation include: STA-5312 (DRUG).
Who is sponsoring clinical trial NCT00088101?
This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.